HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Corneal endothelial cell loss after penetrating keratoplasty in relation to preoperative recipient endothelial cell density.

AbstractAIM:
Our purpose was to assess recipient endothelial cell density and trephination diameter as predictive factors for corneal endothelial cell density after penetrating keratoplasty (PKP).
METHODS:
Forty-eight eyes showing keratoconus (group I, with sufficient recipient endothelial cell density) and 42 eyes demonstrating bullous keratopathy or Fuchs' dystrophy (group II, with insufficient recipient endothelial cell density) were included in this retrospective study. The endothelial cell density after PKP was assessed over 2 years.
RESULTS:
Chronic endothelial cell loss was significantly higher in group II than in group I patients at all follow-up times >3 months (p < 0.05). In group II patients, an inverse correlation between endothelial cell loss and trephine diameter was observed.
CONCLUSION:
This study shows that recipient endothelial cell density is a risk factor for increased endothelial cell loss following PKP. In patients with insufficient endothelial cell density, a large trephine size could reduce chronic endothelial cell loss.
AuthorsSo-Hyang Chung, Hyun Kyung Kim, Man Soo Kim
JournalOphthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde (Ophthalmologica) Vol. 224 Issue 3 Pg. 194-8 ( 2010) ISSN: 1423-0267 [Electronic] Switzerland
PMID19864930 (Publication Type: Journal Article)
Copyright2009 S. Karger AG, Basel.
Topics
  • Adult
  • Cell Count
  • Corneal Endothelial Cell Loss (etiology)
  • Endothelium, Corneal (pathology)
  • Follow-Up Studies
  • Fuchs' Endothelial Dystrophy (pathology, surgery)
  • Humans
  • Keratoconus (pathology, surgery)
  • Keratoplasty, Penetrating
  • Middle Aged
  • Postoperative Complications
  • Preoperative Period
  • Retrospective Studies
  • Risk Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: